International Journal of Drug Delivery Technology
Volume 15, Issue 2

Development and Characterization of Modified Release Dosage Form Utilizing Semaglutide

Aanchal Dangi*, Komal Sharma 

Bhupal Noble's Institute of Pharmaceutical Science, Bhupal Noble's University Udaipur, Rajasthan

Received: 15th Jan, 2025; Revised: 22nd Mar, 2025; Accepted: 10th Apr, 2025; Available Online: 25th Jun, 2025

ABSTRACT

An agonist of the glucagon-like peptide-1 (GLP-1) receptor, semaglutide, when administered as a pure medication solution, has a significant degree of variability in bioavailability due to its low solubility and low permeability. This variability is reflected in the wide range of plasma concentration values (5.85–38.14), affecting its therapeutic effectiveness. The present study aimed to develop and characterize a modified-release dosage form (FPR-8) to enhance the pharmacokinetic profile of Semaglutide by ensuring controlled and sustained drug release over 24 hours, thereby reducing fluctuations in plasma concentration and improving bioavailability. The optimized formulation FPR-8 was developed and evaluated for its drug release profile, pharmacokinetic parameters, and in vivo performance in animal models. The improved formulation's plasma concentration values were contrasted with those of a pure drug solution. Administration of FPR-8 resulted in significantly reduced variability in plasma concentration values (4.12–19.46) compared to the pure drug suspension. The controlled-release formulation facilitated slow and gradual absorption, ensuring prolonged systemic circulation of Semaglutide over 24 hours. This sustained-release effect contributed to enhanced bioavailability and reduced fluctuations, addressing the limitations associated with the pure drug's pharmacokinetic profile. The development of a modified-release dosage form (FPR-8) successfully optimized the pharmacokinetic behavior of Semaglutide, ensuring consistent absorption, prolonged circulation, and reduced intersubject variability. This approach holds promise for improving therapeutic efficacy and patient compliance in the clinical use of Semaglutide.

Keywords: Semaglutide, modified-release formulation, bioavailability, pharmacokinetics, sustained release, drug absorption.

How to cite this article: Aanchal Dangi, Komal Sharma. Development and Characterisation of Modified Release Dosage Form Utilizing Semaglutide. International Journal of Drug Delivery Technology. 2025;15(2):592-99. doi: 10.25258/ijddt.15.2.28

REFERENCES

  1. Maharjan R, Lim DS, Baik HJ, Park HE, Kim MS, Kim KH, Jeong SH. Preparation of semaglutide long-acting injectable microcapsules with physicochemical properties, long-term stability, and pharmacokinetics and pharmacodynamics. J Pharm Investig. 2024;54(5):667–81.​
  2. Alhashem G, Raghif ARA, Abbas AA. The Effects of Liraglutide on Biochemical Markers of Bone Turnover in Rats Treated by Dexamethasone. International Journal of Drug Delivery Technology. 2022;12(2):598-602.
  3. Zeng H, Song J, Li Y, Guo C, Zhang Y, Yin T, et al. Effect of hydroxyethyl starch on drug stability and release of semaglutide in PLGA microspheres. Int J Pharm. 2024;654:123991.​
  4. Bhavani MS, Saravanan R. Beyond Syringes and Pills: Advances in Drug Delivery Systems for Diabetes. International Journal of Drug Delivery Technology. 2023;13(3):1069-1077.
  5. Manasa M, Aanandhi VM. Stability indicating method development and validation of semaglutide by RP-HPLC in pharmaceutical substance and pharmaceutical product. Res J Pharm Technol. 2021;14(3):1385–9.​
  6. Barzeh H, Sogali BS, Shadvar S. A review on extended release matrix tablet. J Pharm Res. 2016;15(4):147–52.​
  7. Huang YB, Tsai YH, Yang WC, Chang JS, Wu PC, Takayama K. Once-daily propranolol extended-release tablet dosage form: formulation design and in vitro/in vivo investigation. Eur J Pharm Biopharm. 2004;58(3):607–14.​
  8. Gunde MC, Jambulkar AD, Suruse PB. Formulation and Evaluation of Extended-release Capsule of Propranolol Hydrochloride. International Journal of Drug Delivery Technology. 2022;12(3):1282-1285.
  9. Mansour NM, El-Masry AA, El-Sherbiny DT, Moustafa MA. Blueness, Whiteness, and greenness Appraisal of sensitive chromatographic approach for determination of semaglutide concurrently with Pioglitazone and metformin using green mobile phase; alongside with pharmacokinetic study. Microchem J. 2024;207:111686.​
  10. Indian Pharmacopoeia Commission. Indian Pharmacopoeia. 8th ed. Vol. 1. Ghaziabad: Indian Pharmacopoeia Commission; 2018.​
  11. Wang B, Su Z, Kuang M, Luo Y, Xu M, Sun M, et al. Chitosan hydrochloride coated and nonionic surfactant modified niosomes: a better way for oral administration of semaglutide. Biomed Mater. 2025.​
  12. Bairagee D, Verma P, Jain N, Jain N. Fabrication and in vitro characterization of Niosomal formulations for controlled delivery of ranitidine HCl. Lat Am J Pharm. 2022;41(1):85–91.​
  13. Lewis AL, McEntee N, Holland J, Patel A. Development and approval of Rybelsus (oral semaglutide): ushering in a new era in peptide delivery. Drug Deliv Transl Res. 2022;12(1):1–6.​
  14. Yang W, Gadgil P, Krishnamurthy VR, Landis M, Mallick P, Patel D, et al. The evolving druggability and developability space: chemically modified new modalities and emerging small molecules. AAPS J. 2020;22:1–14.